Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Galeterone

Catalog No: tcsc0334

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg

Specifications

CAS No:
851983-85-2

Formula:
$C_{26}H_{32}N_2O$

Pathway:
Metabolic Enzyme/Protease

Target:
Cytochrome P450

Purity / Grade:
>98%

Solubility:
DMSO : 18 mg/mL (46.33 mM; Need ultrasonic and warming)

Alternative Names:
TOK-001;VN-124-1

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Observed Molecular Weight:
388.55

Product Description

TOK-001 is a multifunctional antiandrogen and **CYP17** inhibitor (**IC_{50}**=47 nM) in castration resistant prostate cancer (CRPC).

IC50 & Target: IC50: 47 nM (CYP17)[1]

In Vitro: TOK-001 affords strong CYP17 lyase inhibition, with IC_{50} of 47 nM[1]. TOK-001 is both a CYP17A1 inhibitor and androgen receptor antagonist and the similarity of these binding modes is likely the reason for this dual mechanism of action.This CYP17A1 binds abiraterone and TOK-001 with absorbance decreases at 402 nm and increases at 424 nm, consistent with nitrogen binding to the heme iron (type II interaction) with K_d of [2]. When LNCaP cells are cultured in medium supplemented with charcoal-stripped serum (CSS, T[3].

In Vivo: Mice inoculated with LAPC-4 tumors are treated subcutaneously with 0.15 mmol/kg of TOK-001 twice daily. Mice treated with TOK-001 have smaller average tumor volume on day 31 when compared to control (p= 0.0001). TOK-001 treatment also significantly reduces the growth rate of tumor growth compared to control (p[1].